Defactinib
- Generic Name
- Defactinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21F3N8O3S
- CAS Number
- 1073154-85-4
- Unique Ingredient Identifier
- 53O87HA2QU
- Background
Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Clinical Hub for Interventional Research (CHOIR)
- Target Recruit Count
- 12
- Registration Number
- NCT05636514
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺Concord Repatriation and General Hospital, Sydney, New South Wales, Australia
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 13
- Registration Number
- NCT04720417
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439331
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
- Conditions
- Cancer of the PancreasPancreas CancerPancreas Adenocarcinoma
- Interventions
- Device: Adaptive stereotactic body radiation therapyProcedure: Research blood drawProcedure: Tumor biopsy
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT04331041
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pembrolizumab + Defactinib In Pleural Mesothelioma
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Raphael Bueno, MD
- Registration Number
- NCT04201145
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Trial of Defactinib and VS-6766.
- Conditions
- Low Grade Serous Ovarian CancerNSCLCEndometrioid CarcinomaPancreatic Cancer
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 87
- Registration Number
- NCT03875820
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧The Royal Marsden NHS Foundation Trust - Gynecology Unit, Sutton, United Kingdom
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2025-05-04
- Target Recruit Count
- 36
- Registration Number
- NCT03727880
- Locations
- 🇺🇸
The University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
🇺🇸Samuel Oschin Cancer Center at Cedars-Sinai, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Michael McHale
- Target Recruit Count
- 90
- Registration Number
- NCT03287271
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02913716
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
- Conditions
- Carcinoma, Non-small-cell LungPancreatic NeoplasmsMesothelioma
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 59
- Registration Number
- NCT02758587
- Locations
- 🇬🇧
Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom
🇬🇧Belfast Health and Social Care Trust, Cancer Centre, Lisburn Road, Belfast, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.